@article{PennekampIlesGarlandetal.2019,
  author    = {Pennekamp, Frank and Iles, Alison C. and Garland, Joshua and Brennan, Georgina and Brose, Ulrich and Gaedke, Ursula and Jacob, Ute and Kratina, Pavel and Matthews, Blake and Munch, Stephan and Novak, Mark and Palamara, Gian Marco and Rall, Bjorn C. and Rosenbaum, Benjamin and Tabi, Andrea and Ward, Colette and Williams, Richard and Ye, Hao and Petchey, Owen L.},
  title     = {The intrinsic predictability of ecological time series and its potential to guide forecasting},
  series = {Ecological monographs : a publication of the Ecological Society of America.},
  volume    = {89},
  journal   = {Ecological monographs : a publication of the Ecological Society of America.},
  number    = {2},
  publisher = {Wiley},
  address   = {Hoboken},
  issn      = {0012-9615},
  doi       = {10.1002/ecm.1359},
  pages     = {17},
  year      = {2019},
  language  = {en}
}
@article{PeterWenderingSchlickeiseretal.2022,
  author    = {Peter, Lena and Wendering, D{\´e}sir{\´e}e Jacqueline and Schlickeiser, Stephan and Hoffmann, Henrike and Noster, Rebecca and Wagner, Dimitrios Laurin and Zarrinrad, Ghazaleh and M{\"u}nch, Sandra and Picht, Samira and Schulenberg, Sarah and Moradian, Hanieh and Mashreghi, Mir-Farzin and Klein, Oliver and Gossen, Manfred and Roch, Toralf and Babel, Nina and Reinke, Petra and Volk, Hans-Dieter and Amini, Leila and Schmueck-Henneresse, Michael},
  title     = {Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients},
  series = {Molecular therapy methods and clinical development},
  volume    = {25},
  journal   = {Molecular therapy methods and clinical development},
  publisher = {Cell Press},
  address   = {Cambridge},
  issn      = {2329-0501},
  doi       = {10.1016/j.omtm.2022.02.012},
  pages     = {52 -- 73},
  year      = {2022},
  abstract  = {Solid organ transplant (SOT) recipients receive therapeutic immunosuppression that compromises their immune response to infections and vaccines. For this reason, SOT patients have a high risk of developing severe coronavirus disease 2019 (COVID-19) and an increased risk of death from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Moreover, the efficiency of immunotherapies and vaccines is reduced due to the constant immunosuppression in this patient group. Here, we propose adoptive transfer of SARS-CoV-2-specific T cells made resistant to a common immunosuppressant, tacrolimus, for optimized performance in the immunosuppressed patient. Using a ribonucleoprotein approach of CRISPR-Cas9 technology, we have generated tacrolimus-resistant SARS-CoV-2-specific T cell products from convalescent donors and demonstrate their specificity and function through characterizations at the single-cell level, including flow cytometry, single-cell RNA (scRNA) Cellular Indexing of Transcriptomes and Epitopes (CITE), and T cell receptor (TCR) sequencing analyses. Based on the promising results, we aim for clinical validation of this approach in transplant recipients. Additionally, we propose a combinatory approach with tacrolimus, to prevent an overshooting immune response manifested as bystander T cell activation in the setting of severe COVID-19 immunopathology, and tacrolimus-resistant SARS-CoV-2-specific T cell products, allowing for efficient clearance of viral infection. Our strategy has the potential to prevent severe COVID-19 courses in SOT or autoimmunity settings and to prevent immunopathology while providing viral clearance in severe non-transplant COVID-19 cases.},
  language  = {en}
}